EXTH-50. IDENTIFYING TRIM11 AS A POTENTIAL THERAPEUTIC TARGET FOR MALIGNANT GLIOMAS Article Swipe
Kaijun Di
,
Daniela Abrams
,
Pratik Yadav
,
Bhaskar C. Das
,
Daniela A. Bota
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noac209.848
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noac209.848
TRIM11 (tripartite motif-containing protein 11) belongs to the TRIM/RBCC (the RING B-box coiled-coil) family of E3 ubiquitin ligases. Members of this family have been implicated in development, neurodegenerative diseases, cellular response to viral infection and cancer. Glioblastoma (GBM) is an aggressive infiltrative brain tumor with poor prognosis. Our previous work demonstrated that TRIM11 is over-expressed in high-grade gliomas and promotes proliferation, invasion, migration and tumor growth, suggesting TRIM11 is a target for malignant glioma treatment. Here we reported the effect of TRIM11 on GBM progression in vivo using immunocompromised mice intracranially implanted with GBM xenografts over-expressing TRIM11. The control group mice survived longer than the mice bearing TRIM11 over-expressing xenografts (P< 0.5), suggesting TRIM11 enhances tumor progression in vivo. The oncogenic effect of TRIM11 may be related to its influence on apoptosis pathway as a robust induction of poly (ADP-ribose) polymerase (PARP) was observed in TRIM11 over-expressing GBM cells. PARP could repair DNA damage caused by UV light, radiation, and certain anticancer drugs, etc. Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent for GBM through alkylating/methylating DNA, leading to DNA damage and death of tumor cells. TRIM11 over-expressing GBM cells were found more resistant to TMZ and showed a higher survival rate compared to parental cells, indicating that TRIM11 might be a therapeutic target for GBM. Based on homology modeling we designed and synthesized small library of TRIM11 inhibitors, and identified one compound (BT# 592) significantly inhibited the growth of GBM cells in a dose-dependent manner, implicating that TRIM11 inhibitors may serve as novel agents for malignant glioma treatment. We are in the process to develop more active compounds using SAR studies to identify hit-to-lead compounds as potential therapeutics for GBM.
Related Topics
Concepts
Temozolomide
Cancer research
Biology
In vivo
DNA damage
Apoptosis
Poly ADP ribose polymerase
Glioma
DNA
Polymerase
Biochemistry
Genetics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/neuonc/noac209.848
- https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdf
- OA Status
- bronze
- Cited By
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4309017518
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4309017518Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/neuonc/noac209.848Digital Object Identifier
- Title
-
EXTH-50. IDENTIFYING TRIM11 AS A POTENTIAL THERAPEUTIC TARGET FOR MALIGNANT GLIOMASWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-11-01Full publication date if available
- Authors
-
Kaijun Di, Daniela Abrams, Pratik Yadav, Bhaskar C. Das, Daniela A. BotaList of authors in order
- Landing page
-
https://doi.org/10.1093/neuonc/noac209.848Publisher landing page
- PDF URL
-
https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdfDirect OA link when available
- Concepts
-
Temozolomide, Cancer research, Biology, In vivo, DNA damage, Apoptosis, Poly ADP ribose polymerase, Glioma, DNA, Polymerase, Biochemistry, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4309017518 |
|---|---|
| doi | https://doi.org/10.1093/neuonc/noac209.848 |
| ids.doi | https://doi.org/10.1093/neuonc/noac209.848 |
| ids.openalex | https://openalex.org/W4309017518 |
| fwci | 0.11809339 |
| type | article |
| title | EXTH-50. IDENTIFYING TRIM11 AS A POTENTIAL THERAPEUTIC TARGET FOR MALIGNANT GLIOMAS |
| biblio.issue | Supplement_7 |
| biblio.volume | 24 |
| biblio.last_page | vii220 |
| biblio.first_page | vii220 |
| topics[0].id | https://openalex.org/T11668 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.996999979019165 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | interferon and immune responses |
| topics[1].id | https://openalex.org/T11765 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9909999966621399 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Circular RNAs in diseases |
| topics[2].id | https://openalex.org/T13779 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9812999963760376 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Cancer Mechanisms and Therapy |
| is_xpac | False |
| apc_list.value | 4612 |
| apc_list.currency | USD |
| apc_list.value_usd | 4612 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777389519 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7259502410888672 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q425088 |
| concepts[0].display_name | Temozolomide |
| concepts[1].id | https://openalex.org/C502942594 |
| concepts[1].level | 1 |
| concepts[1].score | 0.6897345781326294 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[1].display_name | Cancer research |
| concepts[2].id | https://openalex.org/C86803240 |
| concepts[2].level | 0 |
| concepts[2].score | 0.6057240962982178 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[2].display_name | Biology |
| concepts[3].id | https://openalex.org/C207001950 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4786221385002136 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[3].display_name | In vivo |
| concepts[4].id | https://openalex.org/C143425029 |
| concepts[4].level | 3 |
| concepts[4].score | 0.4661121964454651 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q5205747 |
| concepts[4].display_name | DNA damage |
| concepts[5].id | https://openalex.org/C190283241 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4633491635322571 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q14599311 |
| concepts[5].display_name | Apoptosis |
| concepts[6].id | https://openalex.org/C182979987 |
| concepts[6].level | 4 |
| concepts[6].score | 0.4557476043701172 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q3907241 |
| concepts[6].display_name | Poly ADP ribose polymerase |
| concepts[7].id | https://openalex.org/C2778227246 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4482000768184662 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1365309 |
| concepts[7].display_name | Glioma |
| concepts[8].id | https://openalex.org/C552990157 |
| concepts[8].level | 2 |
| concepts[8].score | 0.2764953374862671 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7430 |
| concepts[8].display_name | DNA |
| concepts[9].id | https://openalex.org/C82381507 |
| concepts[9].level | 3 |
| concepts[9].score | 0.167324036359787 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q416878 |
| concepts[9].display_name | Polymerase |
| concepts[10].id | https://openalex.org/C55493867 |
| concepts[10].level | 1 |
| concepts[10].score | 0.09098771214485168 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[10].display_name | Biochemistry |
| concepts[11].id | https://openalex.org/C54355233 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0865345299243927 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[11].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/temozolomide |
| keywords[0].score | 0.7259502410888672 |
| keywords[0].display_name | Temozolomide |
| keywords[1].id | https://openalex.org/keywords/cancer-research |
| keywords[1].score | 0.6897345781326294 |
| keywords[1].display_name | Cancer research |
| keywords[2].id | https://openalex.org/keywords/biology |
| keywords[2].score | 0.6057240962982178 |
| keywords[2].display_name | Biology |
| keywords[3].id | https://openalex.org/keywords/in-vivo |
| keywords[3].score | 0.4786221385002136 |
| keywords[3].display_name | In vivo |
| keywords[4].id | https://openalex.org/keywords/dna-damage |
| keywords[4].score | 0.4661121964454651 |
| keywords[4].display_name | DNA damage |
| keywords[5].id | https://openalex.org/keywords/apoptosis |
| keywords[5].score | 0.4633491635322571 |
| keywords[5].display_name | Apoptosis |
| keywords[6].id | https://openalex.org/keywords/poly-adp-ribose-polymerase |
| keywords[6].score | 0.4557476043701172 |
| keywords[6].display_name | Poly ADP ribose polymerase |
| keywords[7].id | https://openalex.org/keywords/glioma |
| keywords[7].score | 0.4482000768184662 |
| keywords[7].display_name | Glioma |
| keywords[8].id | https://openalex.org/keywords/dna |
| keywords[8].score | 0.2764953374862671 |
| keywords[8].display_name | DNA |
| keywords[9].id | https://openalex.org/keywords/polymerase |
| keywords[9].score | 0.167324036359787 |
| keywords[9].display_name | Polymerase |
| keywords[10].id | https://openalex.org/keywords/biochemistry |
| keywords[10].score | 0.09098771214485168 |
| keywords[10].display_name | Biochemistry |
| keywords[11].id | https://openalex.org/keywords/genetics |
| keywords[11].score | 0.0865345299243927 |
| keywords[11].display_name | Genetics |
| language | en |
| locations[0].id | doi:10.1093/neuonc/noac209.848 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S106908163 |
| locations[0].source.issn | 1522-8517, 1523-5866 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1522-8517 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Neuro-Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neuro-Oncology |
| locations[0].landing_page_url | https://doi.org/10.1093/neuonc/noac209.848 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5034839921 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-7901-009X |
| authorships[0].author.display_name | Kaijun Di |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I204250578 |
| authorships[0].affiliations[0].raw_affiliation_string | University of California, Irvine , Irvine, CA , USA |
| authorships[0].institutions[0].id | https://openalex.org/I204250578 |
| authorships[0].institutions[0].ror | https://ror.org/04gyf1771 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I204250578 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | University of California, Irvine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kaijun Di |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | University of California, Irvine , Irvine, CA , USA |
| authorships[1].author.id | https://openalex.org/A5036869940 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Daniela Abrams |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1340111290 |
| authorships[1].affiliations[0].raw_affiliation_string | Mercy Medical Center , Cedar Rapids , USA |
| authorships[1].institutions[0].id | https://openalex.org/I1340111290 |
| authorships[1].institutions[0].ror | https://ror.org/051525m98 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1340111290 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Mercy Medical Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Daniela Abrams |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Mercy Medical Center , Cedar Rapids , USA |
| authorships[2].author.id | https://openalex.org/A5039339055 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4845-4189 |
| authorships[2].author.display_name | Pratik Yadav |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I138873065 |
| authorships[2].affiliations[0].raw_affiliation_string | Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University , New York , USA |
| authorships[2].institutions[0].id | https://openalex.org/I138873065 |
| authorships[2].institutions[0].ror | https://ror.org/0324fzh77 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I138873065 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Long Island University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Pratik Yadav |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University , New York , USA |
| authorships[3].author.id | https://openalex.org/A5045304815 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5837-027X |
| authorships[3].author.display_name | Bhaskar C. Das |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I138873065 |
| authorships[3].affiliations[0].raw_affiliation_string | Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University , New York , USA |
| authorships[3].institutions[0].id | https://openalex.org/I138873065 |
| authorships[3].institutions[0].ror | https://ror.org/0324fzh77 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I138873065 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Long Island University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Bhaskar Das |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University , New York , USA |
| authorships[4].author.id | https://openalex.org/A5041536073 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-9680-9060 |
| authorships[4].author.display_name | Daniela A. Bota |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I204250578 |
| authorships[4].affiliations[0].raw_affiliation_string | University of California Irvine , Irvine, CA , USA |
| authorships[4].institutions[0].id | https://openalex.org/I204250578 |
| authorships[4].institutions[0].ror | https://ror.org/04gyf1771 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I204250578 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | University of California, Irvine |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Daniela Bota |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | University of California Irvine , Irvine, CA , USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | EXTH-50. IDENTIFYING TRIM11 AS A POTENTIAL THERAPEUTIC TARGET FOR MALIGNANT GLIOMAS |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11668 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.996999979019165 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | interferon and immune responses |
| related_works | https://openalex.org/W2235074116, https://openalex.org/W2022503084, https://openalex.org/W2019927904, https://openalex.org/W2041906258, https://openalex.org/W2900295007, https://openalex.org/W1975919648, https://openalex.org/W573094082, https://openalex.org/W2019296828, https://openalex.org/W2061602261, https://openalex.org/W1809005416 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/neuonc/noac209.848 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S106908163 |
| best_oa_location.source.issn | 1522-8517, 1523-5866 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1522-8517 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Neuro-Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neuro-Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/neuonc/noac209.848 |
| primary_location.id | doi:10.1093/neuonc/noac209.848 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S106908163 |
| primary_location.source.issn | 1522-8517, 1523-5866 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1522-8517 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Neuro-Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii220/47020842/noac209.848.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neuro-Oncology |
| primary_location.landing_page_url | https://doi.org/10.1093/neuonc/noac209.848 |
| publication_date | 2022-11-01 |
| publication_year | 2022 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 70, 135, 183, 213, 226, 258 |
| abstract_inverted_index.E3 | 16 |
| abstract_inverted_index.UV | 157 |
| abstract_inverted_index.We | 274 |
| abstract_inverted_index.an | 40 |
| abstract_inverted_index.as | 134, 267, 291 |
| abstract_inverted_index.be | 126, 225 |
| abstract_inverted_index.by | 156 |
| abstract_inverted_index.in | 26, 56, 86, 118, 145, 257, 276 |
| abstract_inverted_index.is | 39, 54, 69, 182 |
| abstract_inverted_index.of | 15, 20, 81, 123, 138, 198, 241, 254 |
| abstract_inverted_index.on | 83, 131, 232 |
| abstract_inverted_index.to | 7, 32, 128, 178, 193, 209, 218, 279, 287 |
| abstract_inverted_index.we | 77, 235 |
| abstract_inverted_index.11) | 5 |
| abstract_inverted_index.DNA | 153, 194 |
| abstract_inverted_index.GBM | 84, 94, 148, 188, 203, 255 |
| abstract_inverted_index.Our | 48 |
| abstract_inverted_index.SAR | 285 |
| abstract_inverted_index.TMZ | 210 |
| abstract_inverted_index.The | 98, 120 |
| abstract_inverted_index.and | 35, 59, 64, 160, 196, 211, 237, 244 |
| abstract_inverted_index.are | 275 |
| abstract_inverted_index.for | 72, 187, 229, 270, 294 |
| abstract_inverted_index.its | 129 |
| abstract_inverted_index.may | 125, 167, 265 |
| abstract_inverted_index.one | 246 |
| abstract_inverted_index.the | 8, 79, 105, 252, 277 |
| abstract_inverted_index.was | 143 |
| abstract_inverted_index.(BT# | 248 |
| abstract_inverted_index.(the | 10 |
| abstract_inverted_index.592) | 249 |
| abstract_inverted_index.DNA, | 175, 191 |
| abstract_inverted_index.GBM. | 230, 295 |
| abstract_inverted_index.Here | 76 |
| abstract_inverted_index.PARP | 150, 166 |
| abstract_inverted_index.RING | 11 |
| abstract_inverted_index.been | 24 |
| abstract_inverted_index.die. | 179 |
| abstract_inverted_index.etc. | 164 |
| abstract_inverted_index.from | 171 |
| abstract_inverted_index.have | 23 |
| abstract_inverted_index.mice | 90, 101, 106 |
| abstract_inverted_index.more | 207, 281 |
| abstract_inverted_index.poly | 139 |
| abstract_inverted_index.poor | 46 |
| abstract_inverted_index.rate | 216 |
| abstract_inverted_index.than | 104 |
| abstract_inverted_index.that | 52, 222, 262 |
| abstract_inverted_index.them | 177 |
| abstract_inverted_index.this | 21 |
| abstract_inverted_index.vivo | 87 |
| abstract_inverted_index.were | 205 |
| abstract_inverted_index.with | 45, 93 |
| abstract_inverted_index.work | 50 |
| abstract_inverted_index.(GBM) | 38 |
| abstract_inverted_index.(TMZ) | 181 |
| abstract_inverted_index.0.5), | 112 |
| abstract_inverted_index.B-box | 12 |
| abstract_inverted_index.Based | 231 |
| abstract_inverted_index.agent | 186 |
| abstract_inverted_index.brain | 43 |
| abstract_inverted_index.cells | 170, 204, 256 |
| abstract_inverted_index.could | 151 |
| abstract_inverted_index.death | 197 |
| abstract_inverted_index.found | 206 |
| abstract_inverted_index.group | 100 |
| abstract_inverted_index.might | 224 |
| abstract_inverted_index.novel | 268 |
| abstract_inverted_index.serve | 266 |
| abstract_inverted_index.small | 239 |
| abstract_inverted_index.their | 173 |
| abstract_inverted_index.tumor | 44, 65, 116, 199 |
| abstract_inverted_index.using | 88, 284 |
| abstract_inverted_index.viral | 33 |
| abstract_inverted_index.vivo. | 119 |
| abstract_inverted_index.(PARP) | 142 |
| abstract_inverted_index.TRIM11 | 1, 53, 68, 82, 108, 114, 124, 146, 201, 223, 242, 263 |
| abstract_inverted_index.active | 282 |
| abstract_inverted_index.agents | 269 |
| abstract_inverted_index.cancer | 169 |
| abstract_inverted_index.caused | 155 |
| abstract_inverted_index.cells, | 220 |
| abstract_inverted_index.cells. | 149, 200 |
| abstract_inverted_index.damage | 154, 195 |
| abstract_inverted_index.drugs, | 163 |
| abstract_inverted_index.effect | 80, 122 |
| abstract_inverted_index.family | 14, 22 |
| abstract_inverted_index.glioma | 74, 272 |
| abstract_inverted_index.growth | 253 |
| abstract_inverted_index.higher | 214 |
| abstract_inverted_index.light, | 158 |
| abstract_inverted_index.longer | 103 |
| abstract_inverted_index.repair | 152 |
| abstract_inverted_index.robust | 136 |
| abstract_inverted_index.showed | 212 |
| abstract_inverted_index.target | 71, 228 |
| abstract_inverted_index.Members | 19 |
| abstract_inverted_index.TRIM11. | 97 |
| abstract_inverted_index.bearing | 107 |
| abstract_inverted_index.belongs | 6 |
| abstract_inverted_index.cancer. | 36 |
| abstract_inverted_index.causing | 176 |
| abstract_inverted_index.certain | 161 |
| abstract_inverted_index.control | 99 |
| abstract_inverted_index.damaged | 174 |
| abstract_inverted_index.develop | 280 |
| abstract_inverted_index.gliomas | 58 |
| abstract_inverted_index.growth, | 66 |
| abstract_inverted_index.leading | 192 |
| abstract_inverted_index.library | 240 |
| abstract_inverted_index.manner, | 260 |
| abstract_inverted_index.pathway | 133 |
| abstract_inverted_index.prevent | 168 |
| abstract_inverted_index.process | 278 |
| abstract_inverted_index.protein | 4 |
| abstract_inverted_index.related | 127 |
| abstract_inverted_index.studies | 286 |
| abstract_inverted_index.through | 189 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Blocking | 165 |
| abstract_inverted_index.cellular | 30 |
| abstract_inverted_index.compared | 217 |
| abstract_inverted_index.compound | 247 |
| abstract_inverted_index.designed | 236 |
| abstract_inverted_index.enhances | 115 |
| abstract_inverted_index.homology | 233 |
| abstract_inverted_index.identify | 288 |
| abstract_inverted_index.ligases. | 18 |
| abstract_inverted_index.modeling | 234 |
| abstract_inverted_index.observed | 144 |
| abstract_inverted_index.parental | 219 |
| abstract_inverted_index.previous | 49 |
| abstract_inverted_index.promotes | 60 |
| abstract_inverted_index.reported | 78 |
| abstract_inverted_index.response | 31 |
| abstract_inverted_index.survival | 215 |
| abstract_inverted_index.survived | 102 |
| abstract_inverted_index.TRIM/RBCC | 9 |
| abstract_inverted_index.apoptosis | 132 |
| abstract_inverted_index.compounds | 283, 290 |
| abstract_inverted_index.diseases, | 29 |
| abstract_inverted_index.implanted | 92 |
| abstract_inverted_index.induction | 137 |
| abstract_inverted_index.infection | 34 |
| abstract_inverted_index.influence | 130 |
| abstract_inverted_index.inhibited | 251 |
| abstract_inverted_index.invasion, | 62 |
| abstract_inverted_index.malignant | 73, 271 |
| abstract_inverted_index.migration | 63 |
| abstract_inverted_index.oncogenic | 121 |
| abstract_inverted_index.potential | 292 |
| abstract_inverted_index.repairing | 172 |
| abstract_inverted_index.resistant | 208 |
| abstract_inverted_index.ubiquitin | 17 |
| abstract_inverted_index.(P&lt; | 111 |
| abstract_inverted_index.aggressive | 41 |
| abstract_inverted_index.anticancer | 162 |
| abstract_inverted_index.high-grade | 57 |
| abstract_inverted_index.identified | 245 |
| abstract_inverted_index.implicated | 25 |
| abstract_inverted_index.indicating | 221 |
| abstract_inverted_index.inhibitors | 264 |
| abstract_inverted_index.polymerase | 141 |
| abstract_inverted_index.prognosis. | 47 |
| abstract_inverted_index.radiation, | 159 |
| abstract_inverted_index.suggesting | 67, 113 |
| abstract_inverted_index.treatment. | 75, 273 |
| abstract_inverted_index.xenografts | 95, 110 |
| abstract_inverted_index.(tripartite | 2 |
| abstract_inverted_index.hit-to-lead | 289 |
| abstract_inverted_index.implicating | 261 |
| abstract_inverted_index.inhibitors, | 243 |
| abstract_inverted_index.progression | 85, 117 |
| abstract_inverted_index.synthesized | 238 |
| abstract_inverted_index.therapeutic | 227 |
| abstract_inverted_index.(ADP-ribose) | 140 |
| abstract_inverted_index.Glioblastoma | 37 |
| abstract_inverted_index.Temozolomide | 180 |
| abstract_inverted_index.coiled-coil) | 13 |
| abstract_inverted_index.demonstrated | 51 |
| abstract_inverted_index.development, | 27 |
| abstract_inverted_index.infiltrative | 42 |
| abstract_inverted_index.therapeutics | 293 |
| abstract_inverted_index.significantly | 250 |
| abstract_inverted_index.dose-dependent | 259 |
| abstract_inverted_index.intracranially | 91 |
| abstract_inverted_index.over-expressed | 55 |
| abstract_inverted_index.proliferation, | 61 |
| abstract_inverted_index.over-expressing | 96, 109, 147, 202 |
| abstract_inverted_index.chemotherapeutic | 185 |
| abstract_inverted_index.motif-containing | 3 |
| abstract_inverted_index.standard-of-care | 184 |
| abstract_inverted_index.immunocompromised | 89 |
| abstract_inverted_index.neurodegenerative | 28 |
| abstract_inverted_index.alkylating/methylating | 190 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7099999785423279 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.43041225 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |